Cullinan Therapeutics Q3 operating income beats analyst expectations as expenses fall

Overview

• U.S. biopharma firm's Q3 operating income beat analyst expectations as expenses declined yr/yr

• Net loss for Q3 narrowed slightly from prior year

• Company ended Q3 with $313.8 mln in cash and investments, expects runway into 2029

Outlook

• Cullinan expects its cash resources to provide runway into 2029 under its current operating plan

• Company to share CLN-978 multi-dose regimen data in SLE, RA, and Sjögren’s disease in December

• Completion of zipalertinib NDA submission for first-line EGFR ex20ins NSCLC expected in November

Result Drivers

• LOWER EXPENSES - Co attributed reduced R&D and G&A expenses to lower spending in Q3 compared to prior year

• PIPELINE PROGRESS - Co highlighted advancement of clinical programs, including initiation of new studies and regulatory milestones in autoimmune and oncology indications

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Cullinan Therapeutics, Inc. is $35.50, about 202.6% above its November 9 closing price of $11.73

Reuters Recommended Reads

• Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028

• Nov 9 - Maze Therapeutics Q3 results miss estimates on higher R&D spending

• Nov 9 - Compass Therapeutics Q3 net loss widens on higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)